Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up

Journal of Coloproctology - Tập 39 - Trang 115-120 - 2019
Mahsa Mahdipour1, Afshin Shafaghi2, Fariborz Mansour-Ghanaei1, Amineh Hojati3, Farahnaz Joukar3, Sara Mavaddati1
1Guilan University of Medical Sciences (GUMS), Gastrointestinal and Liver Diseases Research Center (GLDRC), Rasht, Iran
2Guilan University of Medical Sciences (GUMS), GI Cancer Screening and Prevention Research Center (GCSPRC), Rasht, Iran
3Guilan University of Medical Sciences (GUMS), Caspian Digestive Diseases Research Center (CDDRC), Rasht, Iran

Tóm tắt

Abstract

Objective Ulcerative colitis usually affects the rectum and potentially can involve the whole colon. Noninvasive methods such as fecal calprotectin measurement may be considered as a reliable and inexpensive approach in assessing disease severity or treatment change strategy.

Methods In this retrospective cross-sectional study, records of 56 ulcerative colitis patients who hospitalized with exacerbation between May 2016 and April 2017 were assessed based on IBD Data Bank Software in Gastrointestinal and Liver Diseases and Research Center (GLDRC), Guilan province, Iran between. A questionnaire of demographic characteristics, clinical findings and fecal calprotectin level was completed. Montreal classification severity of ulcerative colitis and Mayo disease activity index were scored. Data were analyzed for descriptive and analytical analysis.

Results Fecal calprotectin was significantly different in terms of disease severity based on both Mayo score (p = 0.007) and Montreal classification (p = 0.001). In patients with mild symptoms, no increase in fecal calprotectin was observed, but in patients with moderate and severe elevations in fecal calprotectin levels was significant. Also, C-Reactive Protein surge was related to disease severity (p = 0.02). Furthermore, regression comparison among high-chance patients based on fecal calprotectin was significantly related to higher Erythrocyte Sedimentation Rate levels and smoking, p = 0.01 and p = 0.05, respectively.

Conclusion It seems fecal calprotectin levels are related to the disease severity. Non-invasive methods, such as fecal calprotectin assay, may seem to be an alternative to aggressive, costly and time-consuming methods, such as colonoscopy and biopsy, to reduce the suffering of patients and ultimately help improve the patients’ life quality.


Tài liệu tham khảo

Burisch, 2015, The epidemiology of inflammatory bowel disease, Scand J Gastroenterol, 50, 942, 10.3109/00365521.2015.1014407 Gardenbroek, 2012, Surgery for Crohn's disease: new developments, Dig Surg, 29, 275, 10.1159/000341567 Podolsky, 2002, The current future understanding of inflammatory bowel disease, Best Pract Res Clin Gastroenterol, 16, 933, 10.1053/bega.2002.0354 Ogorek, 1994, Differentiation between Crohn's disease and ulcerative colitis, Med Clin North Am, 78, 1249, 10.1016/S0025-7125(16)30098-0 Wilkins, 2011, Diagnosis and management of Crohn's disease, Am Fam Physician, 84, 1365 Festen, 2011, A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease, PLoS Genet, 7, e1001283, 10.1371/journal.pgen.1001283 Hyams, 2011, Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension, Curr Med Res Opin, 27, 651, 10.1185/03007995.2010.547575 Person, 2007, Restorative operations for Crohn's disease, Clin Colon Rectal Surg, 20, 314, 10.1055/s-2007-991031 Tontini, 2015, Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives, World J Gastroenterol, 21, 21, 10.3748/wjg.v21.i1.21 Loftus, 1998, Crohn's disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival, Gastroenterology, 114, 1161, 10.1016/S0016-5085(98)70421-4 Betteridge, 2013, Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the US military health care population, Inflamm Bowel Dis, 19, 1421, 10.1097/MIB.0b013e318281334d Misra, 2018, Epidemiology of inflammatory bowel disease in racial and ethnic migrant groups, World J Gastroenterol, 24, 424, 10.3748/wjg.v24.i3.424 Munkholm, 1992, Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962–87: a sixfold increase in incidence, Scand J Gastroenterol, 27, 609, 10.3109/00365529209000127 Trallori, 1996, A population-based study of inflammatory bowel disease in Florence over 15 years (1978–92), Scand J Gastroenterol, 31, 892, 10.3109/00365529609051998 Safarpour, 2013, Epidemiology of inflammatory bowel diseases in Iran and Asia: a mini review, Iran J Med Sci, 38, 140 Mansour-Ghanaei, 2015, Epidemiologic features of inflammatory bowel disease in Guilan Province, North of Iran, during 2002–2012, Middle East J Dig Dis, 7, 69 Schröder, 2007, Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin, Aliment Pharmacol Ther, 26, 1035, 10.1111/j.1365-2036.2007.03457.x Trzeciak-Jędrzejczyk, 2017, The role of adhesion molecules in inflammatory bowel disease in children. Assessment of the possible risk of cardiovascular complications, Prz Gastroenterol, 12, 181 Walsham, 2016, Fecal calprotectin in inflammatory bowel disease, Clin Exp Gastroenterol, 9, 21 Lehmann, 2015, The role and utility of faecal markers in inflammatory bowel disease, Therap Adv Gastroenterol, 8, 23, 10.1177/1756283X14553384 Schoepfer, 2010, Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI, Am J Gastroenterol, 105, 162, 10.1038/ajg.2009.545 Yui, 2003, Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity, Biol Pharm Bull, 26, 753, 10.1248/bpb.26.753 Champaiboon, 2009, Calprotectin S100A9 calcium-binding loops I and II are essential for keratinocyte resistance to bacterial invasion, J Biol Chem, 284, 7078, 10.1074/jbc.M806605200 Liu, 2012, Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut, Cell Host Microbe, 11, 227, 10.1016/j.chom.2012.01.017 Urban, 2009, Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans, PLoS Pathog, 5, e1000639, 10.1371/journal.ppat.1000639 Lamb, 2011, Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease, Frontline Gastroenterol, 2, 13, 10.1136/fg.2010.001362 Stříž, 2004, Calprotectin—a pleiotropic molecule in acute and chronic inflammation, Physiol Res, 53, 245, 10.33549/physiolres.930448 Guerrant, 1992, Measurement of fecal lactoferrin as a marker of fecal leukocytes, J Clin Microbiol, 30, 1238, 10.1128/JCM.30.5.1238-1242.1992 Salama, 2008, A review of the S100 proteins in cancer, Eur J Surg Oncol, 34, 357, 10.1016/j.ejso.2007.04.009 Erbayrak, 2009, The role of fecal calprotectin in investigating inflammatory bowel diseases, Clinics, 64, 421, 10.1590/S1807-59322009000500009 Schroeder, 1987, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis, N Engl J Med, 317, 1625, 10.1056/NEJM198712243172603 Peyrin-Biroulet, 2016, Defining disease severity in inflammatory bowel diseases: current and future directions, Clin Gastroenterol Hepatol, 14, 348, 10.1016/j.cgh.2015.06.001 Konikoff, 2006, Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease, Inflamm Bowel Dis, 12, 524, 10.1097/00054725-200606000-00013 Wang, 2013, Faecal calprotectin concentrations in gastrointestinal diseases, J Int Med Res, 41, 1357, 10.1177/0300060513488499 Costa, 2005, Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease, Gut, 54, 364, 10.1136/gut.2004.043406 Kawashima, 2016, Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis, BMC Gastroenterol, 16, 47, 10.1186/s12876-016-0462-z Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001 To, 2016, Systematic review with meta analysis: the effect of tobacco smoking on the natural history of ulcerative colitis, Aliment Pharmacol Ther, 44, 117, 10.1111/apt.13663 Ryan, 2014, An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer, J Cancer Epidemiol, 38, 583, 10.1016/j.canep.2014.07.003 ZareMehrjardi, 2010, Comparison of fecal calprotectin level in inflammatory bowel disease and irritable bowel syndrome, Govaresh, 14, 275 Rm, 2013 Burri, 2012, Faecal calprotectin: a useful tool in the management of inflammatory bowel disease, Swiss Med Wkly, 142, w13557 Tibble, 2000, Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease, Gastroenterology, 119, 15, 10.1053/gast.2000.8523 Henderson, 2012, The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease, Am J Gastroenterol, 107, 941, 10.1038/ajg.2012.33
Thông tin
Thông tin xuất bản

Journal of Coloproctology

Tập 39

115-120

Thông tin tác giả